BASF and cell therapy institute CTIBiotech have announced the results of their joint research on 3D tissue models for the development and testing of bio-actives for skin care applications, with scientists revealing they have been able to improve BASF’s 3D skin model using CTIBiotech’s 3D human sebaceous gland technology.

Following two years of research, the companies presented their results at NYSCC Cosmetic Congress, with experts demonstrating both the ex vivo production of physiological sebum in a long-term culture of a 3D human sebaceous gland model, and the regulation of this sebum production by means of active ingredients.

The new CTIBiotech technology was said to have assisted the BASF 3D skin model and aided researchers looking to assess the function of sebaceous glands with regards to skin disorders including age-related, microbial and inflammatory.

BASF’s Project Lead Dr. Sabine Pain, “Compared to current in vitro methods, the 3D models developed by CTIBiotech allow analysis more in touch with human physiology and sebaceous gland metabolism.
“That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications, and in particular skincare products for oily skin.”

Professor Colin McGuckin, Chief Scientific Officer and President of CTIBiotech continued, “Because of their experience and expertise in developing solutions for the dermo-cosmetics market, BASF understands the benefits of collaborating with tissue engineering experts. “The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows us to fully reproduce micro-glands into a full thickness skin model, in vitro.”